Effect of Cilostazol on the Pharmacokinetics and Pharmacodynamics of Warfarin

Authors: Mallikaarjun S.1; Bramer S.L.1

Source: Clinical Pharmacokinetics, Volume 37, Supplement 2, 1999 , pp. 79-86(8)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Objective: To evaluate the effect of cilostazol administration on warfarin pharmacokinetics and pharmacodynamics following a single 25mg dose of warfarin.

Design: A randomised double-blind 2-period crossover with healthy volunteers receiving either 100mg cilostazol twice daily for 13 days or matching placebo twice daily for 13 days, and the other treatment 21 days later. A single 25mg dose of warfarin was given 14 days prior to the start of the study, and 7 days after the cilostazol and placebo treatments.

Study Participants: 15 normal healthy male volunteers.

Outcome Measures: Noncompartmental pharmacokinetic parameters for (R)- and (S)-warfarin, the area under the curve of the prothrombin time (AUCPT), activated partial thromboplastin time (AUCaPTT), Ivy bleeding times, unbound fraction (f) of cilostazol, and warfarin were determined for each individual.

Results: For (R)- and (S)-warfarin, the 90% confidence intervals for the ratios of the geometric means (90% CI) of the maximum plasma concentration and area under the plasma concentration-time curve were between 0.88 to 1.03. The 90% CI for the AUCPT and AUCaPTT was between 0.95 and 1.06. For Ivy bleeding time, the 90% CI for the ratios of the geometric means ranged between 0.71 and 1.22. The f of cilostazol did not differ significantly between the 2 treatments. There was a 17% increase in the f of warfarin (p < 0.05), which was not clinically significant.

Conclusions: Coadministration of warfarin with twice daily administration of cilostazol 100mg did not alter (R)- and (S)-warfarin pharmacokinetics, prothrombin time, partial thromboplastin time, Ivy bleeding times, or cilostazol protein binding.

Keywords: Anticoagulants, drug interactions; Antiplatelets, drug interactions; Cilostazol, drug interactions; Drug interactions; Warfarin, drug interactions

Language: English

Document Type: Original article

Affiliations: 1: Otsuka America Pharmaceutical, Inc., Rockville, Maryland, USA *

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$57.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A